Report Company Directory
- BPMX: Positive feedback from the FDA received with respect to the Phase III design by Zacks
- BPMX: Positive data from Phase IIb of BPX01 for acne announced, by Zacks
- BPMX: Positive top line data from Phase IIb of BPX01 for acne announced by Zacks
- Positive data from Phase IIa of BPX01 for acne announced, Phase IIb initiated. Phase IV of VI2LET initiated, data expected by the end of 2016; by Zacks
- BPMX: Strong balance sheet, Positive data from Phase IIa of BPX01 for acne announced, Phase IIb initiated. Phase IV of VI2LET initiated, data expected in 2017; by Zacks
- BPMX: Progress made in both commercial product and clinical programs Buy by Zacks
- BPMX: Phase IV of VI2LET initiated, data expected by the end of 2016; Phase IIa of BPX01 for acne completed enrollment, data expected in mid-2016. by Zacks
- BPMX: Phase IV of VI2LET initiated, data expected by the end of 2016; Phase IIa of BPX01 for acne completed enrollment, data expected in mid-2016. by Zacks
- BPMX: Phase IIa of BPX01 for acne initiated Buy by Zacks
- BPMX: A specialty pharma company with a focus on women s health and dermatology initiating with Buy rating by Zacks
- INVEST SECURITIES - BIOPHYTIS : Lève près de 2,6m€ pour étendre sa visibilité au T3 25 - ACHAT, 0,77€ vs 0,82€ by Invest Securities
- INVEST SECURITIES - BIOPHYTIS : Quand un effet indésirable devient une opportunité - ACHAT vs NEUTRE, OC 0,82€ vs 2,21€ by Invest Securities
- INVEST SECURITIES - BIOPHYTIS : Lancement de la Ph II OBA autorisé par la FDA - NEUTRE, OC 2,21€ by Invest Securities
- INVEST SECURITIES - BIOPHYTIS : Accord de licence en Amérique latine pour 108m€ (NEUTRE, OC 2,21€) by Invest Securities
- Biophytis | 1K | Under Review | Signs a licencing deal for the LATAM region by Kepler Cheuvreux
- INVEST SECURITIES - BIOPHYTIS : OBA passe, naturellement, en tête des priorités - NEUTRE, OC 2,21€ vs 0,02€ by Invest Securities